TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Maze Therapeutics, Inc. ( (MAZE) ) has shared an update.
On September 2, 2025, Maze Therapeutics, Inc. announced the appointment of Misbah Tahir as the new Chief Financial Officer. Tahir, who previously held finance leadership roles at IGM Biosciences, Dermira, Onyx Pharmaceuticals, and Human Genome Sciences, will be responsible for overseeing the company’s financial operations. His compensation package includes a base salary, bonuses, stock options, and severance benefits, highlighting Maze Therapeutics’ commitment to attracting experienced leadership to strengthen its financial strategy.
The most recent analyst rating on (MAZE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Maze Therapeutics, Inc. stock, see the MAZE Stock Forecast page.
Spark’s Take on MAZE Stock
According to Spark, TipRanks’ AI Analyst, MAZE is a Neutral.
Maze Therapeutics shows strong financial performance with significant revenue and cash flow improvements, yet the negative equity presents a substantial risk. Technical indicators suggest potential weakness in stock momentum, and lack of valuation metrics prevents a comprehensive assessment. Overall, the stock’s strengths in financial growth are tempered by balance sheet risks and technical analysis concerns.
To see Spark’s full report on MAZE stock, click here.
More about Maze Therapeutics, Inc.
Average Trading Volume: 178,513
Technical Sentiment Signal: Strong Buy
Current Market Cap: $635.4M
See more data about MAZE stock on TipRanks’ Stock Analysis page.